Adipokines, metabolic dysfunction and illness course in bipolar disorder

Area of Science:

• Neuroscience
• Metabolic Psychiatry
• Endocrinology

Background:

• Metabolic comorbidities significantly impact bipolar disorder (BD) outcomes.
• Adipokines, signaling molecules from adipose tissue, may play a role in BD pathophysiology and metabolic disturbances.
• Understanding the interplay between adipokines, metabolic health, and BD course is crucial for improved patient management.

Purpose of the Study:

• To investigate the role of adiponectin and leptin in the course of bipolar disorder (BD).
• To examine the relationship between adipokine levels and metabolic comorbidities in BD patients.
• To determine if adiponectin levels predict clinical outcomes and functioning in BD.

Main Methods:

• Plasma levels of adiponectin and leptin were measured in 59 BD patients and 28 healthy controls.
• Anthropometric and metabolic parameters, including glucose, insulin, lipids, and BMI, were assessed.
• Statistical analyses correlated adipokine levels with metabolic markers and clinical outcomes, adjusting for confounders.

Main Results:

• Female BD patients exhibited lower adiponectin levels compared to healthy controls.
• In BD patients, adiponectin correlated with glucose, insulin resistance, HDL, VLDL, and triglycerides.
• Low adiponectin (< 7.5 μg/ml) was independently associated with more mood episodes, fewer hospitalizations, increased depressive symptoms, and lower functioning in BD.

Conclusions:

• Adiponectin levels are significantly lower in female BD patients and are linked to metabolic dysfunction.
• Low adiponectin is an independent predictor of a more severe and unfavorable course of illness in bipolar disorder.
• Adiponectin may serve as a potential biomarker for metabolic disturbances and clinical outcomes in BD.